Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Glaucoma: Overview01:25

Glaucoma: Overview

623
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
623
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

565
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
565

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and staff experiences of a community-based diagnostic clinic for chronic eye conditions: Qualitative analysis.

Eye (London, England)·2026
Same author

Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage.

Scientific reports·2026
Same author

Assessing the Fragility of Statistically Significant Outcomes in Randomized Controlled Trials of Minimally Invasive Glaucoma Surgery (MIGS).

American journal of ophthalmology·2026
Same author

Novel therapeutic strategies to restore vision in ocular hypotony (STRETCH): results from a prospective pilot series.

The British journal of ophthalmology·2026
Same author

Fields from home: device-independent online perimetry with Melbourne Rapid Fields.

The British journal of ophthalmology·2026
Same author

Cohort profile: Design and methods for Project HERCULES (Healthcare Exemplar for Recovery from COVID 19 Using Linear Examination Systems): Multi-disciplinary implementation and evaluation of an asynchronous review clinic in NHS eye-care services.

PloS one·2025

Related Experiment Video

Updated: Jul 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Cell-Based Therapies for Glaucoma.

Joshua Luis1, Karen Eastlake1, William D B Lamb1

  • 1NIHR Biomedical Research Centre for Ophthalmology, UCL Institute of Ophthalmology & Moorfields Eye Hospital, London, UK.

Translational Vision Science & Technology
|July 26, 2023
PubMed
Summary
This summary is machine-generated.

Glaucoma treatments are exploring cell-based therapies to restore vision. These innovative approaches aim to regenerate retinal cells or use cell products to support optic nerve health.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.7K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

Related Experiment Videos

Last Updated: Jul 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.7K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

Area of Science:

  • Ophthalmology and Regenerative Medicine
  • Neuroscience and Cell Biology

Background:

  • Glaucomatous optic neuropathy (GON) is a leading cause of irreversible blindness globally, characterized by retinal ganglion cell (RGC) degeneration and optic nerve head (ONH) remodeling.
  • Elevated intraocular pressure is the primary modifiable risk factor, but current treatments do not restore lost vision.
  • Understanding retinal regeneration in species like zebrafish offers insights into regenerative signaling pathways.

Purpose of the Study:

  • To review current and emerging cell-based therapeutic strategies for glaucoma.
  • To highlight the potential of endogenous regeneration, cell transplantation, and cell-derived products in treating GON.
  • To identify critical factors for translating these therapies into clinical practice.

Main Methods:

  • Review of research on zebrafish retinal regeneration mechanisms.
  • Analysis of in vitro differentiation protocols for retinal cells from stem cells.
  • Evaluation of cell-based products like neurotrophins, microRNA, and extracellular vesicles for RGC and ONH support.

Main Results:

  • Regenerative signaling pathways are being elucidated, but neuronal integration and brain projection remain challenges.
  • In vitro methods can derive retinal cells from various sources, including stem cells.
  • Cell-derived products offer a promising alternative by supporting existing structures without cell replacement.

Conclusions:

  • Cell-based therapies, including endogenous regeneration, cell implantation, and cell-derived products, show significant promise for glaucoma treatment.
  • Successful clinical translation requires optimized cell sourcing, differentiation, and implantation techniques.
  • These approaches may target earlier disease stages and offer functional support to vulnerable retinal components.